SCHEMBL3246687

SCHEMBL3246687

CC(C#N)N(CC(=O)O)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
HPGD P15428 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
NPBWR1 P48145 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MCHR1 Q99705 1/20 0.42
CTSS P25774 3/20 0.42
CTSL P07711 2/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
CTSK P43235 1/20 0.39
MAOB P27338 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3235384 0.98 KMT2A (0.43) KMT2AMEN1HPGDGAATSHR
SCHEMBL2565075 0.85 ALDH1A1 (0.50) KMT2AMEN1HPGDGAATSHR
SCHEMBL12869897 0.82 MEN1 (0.54) KMT2AMEN1HPGDTSHRALDH1A1
Hydrochloric Acid SCHEMBL5847443 0.79 LMNA (0.54) KMT2AMEN1GAATSHRNPBWR1
SCHEMBL347257 0.79 MEN1 (0.56) KMT2AMEN1HPGDALDH1A1LMNA
SCHEMBL22370929 0.79 MEN1 (0.56) KMT2AMEN1HPGDALDH1A1LMNA
SCHEMBL27171240 0.79 MEN1 (0.56) KMT2AMEN1HPGDALDH1A1LMNA
SCHEMBL20135421 0.78 KMT2A (0.46) KMT2AMEN1HPGDGAATSHR
SCHEMBL20135418 0.78 KMT2A (0.46) KMT2AMEN1HPGDGAATSHR
SCHEMBL7137696 0.74 PGR (0.34) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1589029-B1 Pyrazinone protease inhibitors ORTHO MCNEIL PHARM INC (US) 2010-03-17 EP claimed
US-6506761-B1 Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: CORVAS INTERNATIONAL, INC. 2003-01-14 US disclosed
US-6506760-B1 Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: CORVAS INTERNATIONAL, INC. 2003-01-14 US disclosed
EP-1017393-A4 PYRAZINONE THROMBIN INHIBITORS MERCK & CO INC (US) 2002-01-23 EP disclosed
EP-0934305-A4 INTEGRIN ANTAGONISTS MERCK & CO INC (US) 2001-04-11 EP disclosed
EP-1017393-A1 PYRAZINONE THROMBIN INHIBITORS Merck & Co., Inc. (US) 2000-07-12 EP disclosed
EP-0934305-A1 INTEGRIN ANTAGONISTS Merck & Co., Inc. (US) 1999-08-11 EP disclosed
WO-1999011267-A1 PYRAZINONE THROMBIN INHIBITORS MERCK & CO., INC. (US) 1999-03-11 WO disclosed
WO-1998008840-A1 INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 1998-03-05 WO disclosed